Pages that link to "Q72561763"
Jump to navigation
Jump to search
The following pages link to Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine (Q72561763):
Displaying 50 items.
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (Q22305681) (← links)
- Efficacy and tolerability of second-generation antidepressants in social anxiety disorder (Q24656009) (← links)
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders (Q27009995) (← links)
- The evidence-based pharmacotherapy of social anxiety disorder (Q28262456) (← links)
- Deciphering the sinus tachycardias (Q28262583) (← links)
- The neurobiology of social phobia: from pharmacotherapy to brain imaging (Q31837126) (← links)
- Serotonergic agents in the treatment of social phobia in children and adolescents: a case series (Q33739605) (← links)
- Current treatments of the anxiety disorders in adults (Q33795331) (← links)
- Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats (Q33873383) (← links)
- A review of the epidemiology and approaches to the treatment of social anxiety disorder (Q33897217) (← links)
- Future antidepressants: what is in the pipeline and what is missing? (Q33980902) (← links)
- Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. (Q34001596) (← links)
- Social anxiety disorder. (Q34010741) (← links)
- Social phobia. Epidemiology and cost of illness (Q34048572) (← links)
- Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders (Q34086053) (← links)
- Management of anxiety disorders: the added challenge of comorbidity (Q34218830) (← links)
- Pharmacological treatment of social anxiety disorder: a meta-analysis (Q34219988) (← links)
- Psychopharmacology of anxiety disorders (Q34228150) (← links)
- The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety (Q34241289) (← links)
- Social anxiety disorder in childhood and adolescence: current status and future directions (Q34270886) (← links)
- Depression and anxiety disorders (Q34295484) (← links)
- Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment. (Q34317695) (← links)
- Neurobiology and pharmacotherapy of social phobia (Q34366903) (← links)
- Anxiety disorders and major depression, together or apart (Q34415535) (← links)
- Symptomatic and functional assessment of social anxiety disorder in adults (Q34448976) (← links)
- Pharmacotherapy of social anxiety disorder at the turn of the millennium (Q34449008) (← links)
- Pharmacotherapy of social anxiety disorder (Q34500654) (← links)
- Multidimensional effects of sertraline in social anxiety disorder (Q34561653) (← links)
- Serotonergic drugs in the treatment of depressive and anxiety disorders (Q34982492) (← links)
- Pharmacotherapy of anxious disorders (Q35011794) (← links)
- Hyperhidrosis in social anxiety disorder (Q35034405) (← links)
- Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review (Q35054424) (← links)
- Pharmacotherapy of social phobia. (Q35209664) (← links)
- WCA recommendations for the long-term treatment of social phobia. (Q35651410) (← links)
- Optimizing treatment in social phobia: a review of treatment resistance. (Q35901880) (← links)
- Optimal treatment of social phobia: systematic review and meta-analysis (Q35997293) (← links)
- Social anxiety disorder : current treatment recommendations (Q36133813) (← links)
- Fluvoxamine in the treatment of anxiety disorders. (Q36713425) (← links)
- Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study (Q36872999) (← links)
- Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan (Q36942805) (← links)
- Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder (Q37248330) (← links)
- Recent advances in understanding and treating social anxiety disorder. (Q37399886) (← links)
- Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis (Q37610143) (← links)
- Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials (Q37823393) (← links)
- Evidence-based pharmacotherapy for personality disorders (Q37841775) (← links)
- The prediction of response in the anxiety disorders (Q38768842) (← links)
- Recent developments in the psychopharmacology of social phobia (Q40540287) (← links)
- A risk-benefit assessment of buspirone in the treatment of anxiety disorders (Q41380471) (← links)
- Assessment and Treatment of Social Phobia (Q41632606) (← links)
- Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia (Q42677098) (← links)